Drug Profile
Research programme: diabetic nephropathy therapy - Quark Biotech
Latest Information Update: 03 Apr 2007
Price :
$50
*
At a glance
- Originator Quark Biotech
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic nephropathies
Most Recent Events
- 03 Apr 2007 Discontinued - Preclinical for Diabetic nephropathies in USA (unspecified route)
- 15 Mar 2005 Preclinical trials in Diabetic nephropathies in USA (unspecified route)